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Abstract 
We developed an anticancer siRNA delivery system (named HLPR) through modular 
assembly of endogenous molecules. The structure of HLPR was a tightly condensed 
siRNA-peptide inner core in turn surrounded by the disordered lipid layer and thin 
HA coating from which the EGFR-targeted amino acid sequences of 
IVNQPTYGYWHY partially protrude outside of cell surfaces. Both HA and 
IVNQPTYGYWHY anchored on HLPR were responsible for targeting CD44 and 
EGFR overexpressed on the tumor cell surfaces, respectively. HLPR was relatively 
stable in the blood circulation and reached at the tumor tissue in vivo through passive 
and active targeting. Then HLPR entered tumor cells mainly through EGFR-mediated 
pathway followed by the separation of HA from the remaining parts of 
nanocomplexes. The HA-uncoated complexes escaped the endosome through the 
membrane fusion function of DOPE and released cargoes (siRNA and peptide/siRNA) 
in the cytoplasm. HLPR significantly inhibited the growth of implanted subcutaneous 
liver tumors without toxicity.  
 
Keywords: dual targeting, CD44 and EGFR, multifunctional peptide, tumor, HA 
coating 
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Introduction 
 
Chemical drug treatment of tumor 
has been utilized for cancer therapy but 
is associated with non-specific 
cytotoxicity.(1) On the contrary, RNA 
interference (RNAi) mediated through 
small interfering RNA (siRNA) has 
been proved to be a highly efficient and 
promising therapeutic platform for 
malignant and genetic diseases due to its 
ability of target-specific gene silencing 
at post-transcriptional level.(2) Survivin 
is prominently expressed during 
embryonal development and absent in 
most normal.(3) Survivin expression in 
cancer tissues is associated with not only 
apoptosis inhibition but also resistance 
to conventional treatment and 
malignancy of tumors. These features 
make it a unique and important target 
for cancer therapy.(4) Survivin siRNA 
has been considered as an important 
biological drug to silence the survivin 
gene at the mRNA level for tumor 
treatment. SiRNAs are prone to 
degradation by the nucleases in the 
extracellular environment and in 
addition, as anionic macromolecules, 
they are less capable to interact with the 
negative surface of tumor cells.(5) Thus, 
an in vivo suitable delivery vehicle has 
to be developed for siRNA targeting 
transportation in cancer treatment.  
 
To date, poor delivery efficiency in 
vivo is the major hurdle hampering 
expectations in ultimately transforming 
siRNA into clinical practice. Compared 
with the viral siRNA delivery system, 
the non-viral vectors have the 
advantages of unlimited packaging 
capacity and no integration into the 
genome.(6) To successfully deliver 
siRNA to the tumor area and avoid 
nonspecific binding, degradation and 
elimination in the biological fluid, 
development of efficacious delivery 
systems, such as nano-vectors, have 
been applied to improve efficacy and 
overcome several physiological barriers 
of siRNA trafficking.(7) The ideal 
nano-vectors should be utilized for 
“stealth” circulation outside of tumor 
tissues and then successfully pass 
through the leaky endothelium and 
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actively enter into the cancer cells and 
release the cargoes into the cytoplasm.(5) 
To achieve this aim, the nanoparticles 
should not only have suitable sizes and 
enough stability for circulating and 
passing through the tumor vessels but 
also have the abilities for harboring 
various target moieties to actively bind 
receptors that are overexpressed at the 
membrane of tumor cells.(8) 
Furthermore, the siRNA vectors should 
also be able to tackle the intracellular 
barriers and release their cargoes in the 
cytoplasm.(7) 
 
Nanoparticles for siRNA targeted 
delivery have long been studied as a 
particularly promising drug delivery 
vehicle.(9) Many of the targeted 
delivery systems, assembled by cationic 
polymers and amphiphilic compounds, 
have been used to directly introduce 
siRNA into the cancer cells.(10-12) For 
example, Liu et al. reported the 
multifunctional polymer/siRNA 
polyplexes for tumor-targeted siRNA 
delivery,(13) Kostarelos et al. 
constructed the ABCD lipoplexes.(14) 
In addition, the lipopolyplexes 
assembled by 
liposome/protamine/siRNA(15) and 
receptor-targeted nanocomplexes (RTNs) 
designed through modular strategy(16)  
and inorganic nanocomplexes modified 
by biomaterials(17) have been reported 
as anticancer delivery systems. Despite 
these advances, there is no clinical 
product of non-viral vectors that target 
other organs beyond the liver due to 
either high-chemical toxicity of vectors 
or being not very stable in the 
extracellular blood circulation(18). 
Protecting the structure of the 
nano-delivery system until reaching the 
tumor cells is crucial for in vivo targeted 
delivery. In addition, the 
biocompatibility of vectors and the 
antitumor effectiveness of the 
nanoparticles must be fully considered 
during the design process of the delivery 
system. 
 
 CD44 overexpressed at the 
membrane surface of tumor cells is 
distinct from those of the normal tissues, 
and hyaluronic acid (HA) can 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
 3 
specifically target CD44 proteins 
overexpressed at the membrane surface 
of cancer cells but not targeting those of 
the normal cells(19). Thus, HA was 
utilized as the targeting moiety for 
anticancer targeting delivery(20). 
Epidermal growth factor receptor 
(EGFR), as one of the overexpressed 
transmembrane proteins in most cancer 
cells, is also a specific receptor for the 
targeted delivery system for anticancer 
drugs. GE11 (YHWYGYTPQNVI), as 
an EGFR-targeted peptide selected 
through phage display technology,(21) 
was positioned on the surface of 
anticancer drug vectors to achieve 
specific delivery. (22) 
 
 To completely overcome the in vivo 
physiological barriers and achieve 
targeted delivery without safety and 
low-delivery efficiency issues, we have 
recently constructed an optimized 
siRNA delivery system via specific 
penetrating hepatic tumor cells termed 
Q-complexes.(23, 24) In the present 
study, we used GE11 replacing the 
penetrating amine acid sequences 
(KRPTMRFRYTWNPMK)(25) and 
kept unaltered the other compositions to 
construct a tumor dual-targeted drug 
delivery system (termed HLPR). We 
hypothesized that HLPR has similar 
structure with Q-complexes but possess 
dual-targeting moieties to strengthen the 
specific delivery. HLPR also has good 
stability in the blood circulation to 
deliver siRNA to tumors and silence the 
target gene. This work is exploring the 
design of a dual-targeting tumor siRNA 
delivery system by using Food and Drug 
dministration (FDA)-approved 
biomaterials through modular strategy. 
The aim was to develop a suitable 
siRNA targeted delivery system that 
could be utilized for anticancer clinical 
application. 
 
Methods 
 
Animals  
 All animal experiments animals 
were approved by the Laboratory 
Animal Centre of Shanghai Jiao Tong 
University and were performed 
according to the guideline of the 
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National Institutes of Health for the 
humane care and use of laboratory 
animals (NIH publication No. 8023).  
 In vivo imaging  
The major tissues (heart, liver, 
spleen, lung, and kidney) and tumor 
were dissected, collected, and imaged 
using the IVIS Lumina II small-animal 
imaging system (Caliper Life Sciences, 
Alameda, CA, USA). A Cy5 filter set 
was used to acquire Cy5-siRNA 
fluorescence values in vivo. Images 
were acquired and analyzed using the 
Living Image 4.3.1 software (Caliper 
Life Sciences, Alameda, CA, USA). 
 
In vivo biochemical and efficacy assay 
 Mice bearing transplanted 
HCCLM3 hepatic carcinoma were 
established as described in 
Supplementary materials. The in vivo 
function markers of liver and kidney and 
blood glucose were measured on 
Beckman Coulter AU5800 (Beckman 
Coulter, CA, USA) in Shanghai General 
Hospital. After euthanization, the body 
and tumor weights of mice were 
measured. For histological studies, the 
tumors were sectioned at 4 μm and 
examined with hematoxylin–eosin 
(H&E)(26) (Beyotime, Shanghai, China. 
In addition, the TdT-mediated dUTP 
nick-end labeling (TUNEL) staining 
(Bosterbio, CA, USA) and 
immunohistochemistry (IHC) staining 
(Abcam, Cambridge, UK) for survivin 
protein were performed according to the 
manufacturers’ protocols.(27) The 
histological sections were observed 
under an optical microscope (DP72, 
Olympus). 
 
Statistical analysis  
 Data are presented as mean ± 
standard deviation and compared using 
Student’s t-tests. Statistically significant 
differences were expressed as “ns” 
represents p > 0.05, “*” represents p < 
0.05, “**” represents p < 0.01, “***” 
represents p < 0.001. Analyses were 
performed using GraphPad Instat 
software (GraphPad, San Diego, CA, 
USA).  
 
Results 
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Formulation and characterization of 
HLPR 
 A schematic diagram of the 
assembly of HLPR nanocomplexes is 
shown in Figure 1A. First, LPR was 
formed by the assembly of 
DOTAP/DOPE liposome, 
multifunctional peptide (GE11R16), and 
siRNA at the weight ratios of 1:4:1 in 
aqueous solution. The size of LPR was 
81.4 ± 3.2 nm and the zeta potential of 
LPR nanoparticles was +59 ± 0.9 mV 
(Figure 1B). When the weight ratio of 
HA to siRNA was 14:1, the size and zeta 
potential of nanocomplexes did not 
change with further increases of HA to 
siRNA ratios (data not shown). This 
finding indicated that the above weight 
ratio of HA to siRNA completely 
shielded the cationic internal core, and 
this optimized formulation was selected 
for all subsequent studies. Compared 
with LPR, the zeta potential of HLPR 
rapidly reversed to −36 ± 0.6 mV, and 
the size of HLPR slightly increased to 
108 ± 4.07 nm (Figure 1C). The 
morphologies of LPR and HLPR were 
observed with Transmission Electron 
Microscopy (TEM). Sphere shapes with 
a diameter of approximately 50 nm, 
which is smaller than the size examined 
by DLS, was found in all of them. To 
mimic the interference of albumin in 
vivo with the nanocomplexes, LPR and 
HLPR were incubated for 24 h in 5% 
bovine serum. The results showed that 
the size of HLPR kept constant within 
the timeframe tested, whereas the size of 
LPR rapidly increased to 3500 nm and 
then decreased to the original diameters, 
when the charge of LPR reversed from 
positive to negative. The zeta potential 
of HLPR was slightly increased but 
remained negative in the same 
conditions (Figure 1D). At the same 
time, the HLPR size was unchangeable 
in 10% FBS and RPMI-1640 (Table S1) 
within 12 h. Gel electrophoresis assay 
was used to examine the release of 
siRNA in the serum. The result showed 
that siRNA packaged in LPR was 
released within 4 h at 37
 
°C in 67% FBS, 
whereas siRNA packaged in HLPR was 
only released after being incubated for 9 
h at the same condition (Figure 1E). 
This finding indicated that HLPR has 
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 6 
relatively high stability to protect siRNA 
in the serum for more than twice the 
time compared to LPR. The observed 
stability of HLPR is likely attributed to 
LPR being tightly shielded by HA. 
 
Mechanism of cell uptake 
HCCLM3 cells were selected to 
explore the siRNA delivery of HLPR. 
Both Cy5-labeled siRNA and 
fluorescein isothiocyanate labeled HA 
(FITC-HA) were utilized to examine the 
cell uptake efficiency of HLPR. 
Chlorpromazine and 
anti-CD44-antibody were used to inhibit 
the EGFR and CD44-mediated pathways, 
respectively. We found that both HA 
and siRNA entered the cells through the 
CD44-independent and 
EGFR-dependent pathways (Figures 2A 
and B). The internalization of HLPR 
was also investigated through confocal 
laser scanning microscopy (CLSM). 
FITC-HA and Cy5-siRNA were utilized 
to track the signal paths of HA and 
siRNA. We found that most FITC-HA 
and Cy5-siRNA were located together 
but not completely colocalizing at 45 
min (Figure 2C), indicating that some of 
FITC-HA have begun to dissociate from 
Cy5-siRNA at this time point. However, 
we only observed FITC signal and not 
that of Cy5-siRNA at 4 h (Figure 2D). 
This phenomenon demonstrated that HA 
had completely separated from the other 
components of HLPR, indirectly 
supporting the result of the flow 
cytometry assay that showed HLPR was 
first endocytosed, then, HA component 
was separated from the other 
components of HLPR. 
   
siRNA delivery efficiency and 
cytotoxicity of HLPR 
 Lipofectamine 2000 (L2K), as an 
efficient transfection reagent, was used 
as the positive control to investigate the 
transfection efficiency at cell level. The 
cytotoxicity studies (Figure 3A), 
revealed that the viability of HCCLM3 
cells transfected with HLPR or LPR was 
higher than that of L2K. qPCR and 
apoptosis assays (that stained the 
nucleus with Hoechst 33342) also 
showed that HLPR has the capability to 
deliver siRNA to the cell cytoplasm and 
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exert its effects there (Figures 3B and C). 
HLPR containing survivin siRNA 
silenced approximately 90% of the gene 
at the mRNA level compared with that 
of HLPR containing negative siRNA.  
 
In vivo tissue distribution of siRNA and 
the influence of HLPR on the normal 
tissues 
 The in vivo heart, liver, spleen, lung, 
kidney, and tumor distributions of 
siRNA delivered by HLPR were 
examined through tracking the 
fluorescence of Cy5-labeled siRNA. 
Most fluorescence 6 h after 
administration was observed in the 
kidney and tumor of mice in the HLPR 
group as shown in Figure 4A. Moreover, 
the fluorescence of naked Cy5-siRNA 
was only found in the kidney, and little 
fluorescence could be observed in the 
tumor. No Cy5-siRNA was found in the 
heart and spleen. At the same time, very 
little fluorescence was observed in the 
liver and lung. The fluorescence of 
tumors in the HLPR group was nearly 
three times higher than that in mice of 
the siRNA group (p<0.05; Figure 4B). 
To further examine the toxicity of HLPR 
and the influence of HLPR on normal 
tissues, the concentrations of blood 
glucose and those of the conventional 
functional indicators of the liver and 
kidney were tested from the peripheral 
blood following eight administrations of 
siRNA or controls every other day at a 
dose of 1 mg/kg siRNA. As shown in 
Figure 5, the HLPR-survivin group and 
the untreated group had equivalent 
levels at most of the examined indicators. 
It indicated that HLPR was nontoxic in 
vivo and showed no negative effect on 
the normal tissues and the concentration 
of blood glucose. 
 
In vivo antitumor efficacy 
The antitumor efficacy of 
HLPR-survivin siRNA was investigated 
in mice bearing HCCLM3 tumors. From 
the result of tumor volume changes of 
each group (Figure 6A), it was shown 
that the tumors in siRNA and 
HLPR-negative groups grew rapidly 
over time and had no obvious difference 
compared with the tumor growth of the 
untreated group. However, the tumor 
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growth of the HLPR-survivin group was 
significantly inhibited and reached only 
one fourth of the average volume 
compared with the glucose control 
group. As shown in Figure 6B, the 
mouse weights of all groups were not 
affected during repeat administrations, 
indicating that the vectors have no 
toxicity in vivo. The final tumor weights 
(Figure 6C) and the tumor images of 
each group (Figure 6D) also 
demonstrated that the tumors of the 
HLPR-survivin group were significantly 
smaller compared with the other groups. 
 
Then, the tumors from the in vivo 
studies were investigated for cell 
proliferation and apoptosis using H&E 
and TUNEL staining (Figures 7A and B). 
Nuclei of hematoxylin-labeled cells 
were stained blue and the eosin-labeled 
cytoplasms were stained red in H&E. 
Nuclei of proliferating cell nuclear 
antigen (PCNA)-labeled cells were 
stained brown by ABC method in 
TUNEL. Tumors from 
HLPR-survivin-injected mice exhibited 
a markedly higher count of purple and 
brown-colored PCNA-labeled cells 
compared with the control or other 
groups as shown in Figures 7A and 7B, 
respectively. This finding showed more 
advanced and more extensive apoptosis 
and necrosis of tumors in the 
HLPR-survivin group than the other 
treatments. To further elucidate the 
mechanisms of the suppression of 
survivin gene, the HCCLM3 tumors of 
mice were also investigated using the 
IHC assay. As shown in Figure 7C, 
survivin proteins of IHC-positive cells 
were stained brown and the nuclei were 
stained blue. The images indicated that 
the number of brown spots dramatically 
decreased in the HLPR-survivin group 
compared with those in the other groups, 
indicating that the HLPR formulation 
containing survivin siRNA silenced its 
target gene at the protein level. 
 
Discussion 
 
 HLPR was designed through a 
modular strategy, characterized by the 
assembly of each component through 
noncovalent bonding to form various 
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functional nanocomplexes.(23) Without 
the chemical covalence between the 
components, the chemical safety and 
biocompatibility of modular formulation 
were predictable and controllable. We 
focused on EGFR and CD44 
overexpressed on the tumor cell surface 
as the targeted receptors for specific 
delivery of cancer drugs. (28) GE11, an 
EGFR-targeted peptide was used to 
design a novel multifunctional peptide 
(GE11R16, 
IVNQPTYGYWHYRRRRRRRRRRRR
RRRR) for formulating HLPR as the 
similar designed-strategy reported in our 
previous study.
23, 24
 HLPR were 
negatively charged nanocomplexes, the 
physicochemical characteristics of 
which were stable compared with the 
highly positive charge of LPR in the 
serum. This phenomenon indicated that 
HA coated on LPR completely shielded 
the positive surface charge and greatly 
delayed the release time of siRNA in the 
serum (Figure 1E). It showed that HLPR 
is more capable to protect its cargoes 
than LPR in the circulation in vivo.  
 
As reported by Mustapa et al. (29), 
the lipid-peptide-nucleic acid structure 
of LPR should comprise of a tightly 
condensed nucleic acid-peptide inner 
core surrounded by a disordered lipid 
layer, wherein the integrin-targeting 
sequence of the peptide should also 
partially protrude due to the electrically 
neutral amine acid sequences of GE11 
(Figure 1A). The structure of LPR has 
the smart capability for tightly wrapping 
siRNA and actively binding the targeted 
cells compared with cationic 
liposome/siRNA (LR) and 
peptide/siRNA nanocomplexes (PR); 
thus, LPR showed significantly 
enhanced transfection efficiency in vitro 
compared with LR and PR (16). 
However, as a positively charged 
nanocomplex, LPR has the limitation 
that in vivo its targeting capability is 
reduced due to nonspecific binding to 
the negative surface of normal tissues 
and cells. Other caveats of cationic 
nanoparticles include interaction with 
serum components and rapid clearance 
from the circulation. Anionic 
nanocomplexes are now being 
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investigated further by different groups 
as an approach to circumvent the 
problems associated with the in vivo use 
of cationic nanoparticles. Anionic 
formulations have been used for siRNA 
silencing with promising results, 
including tumor targeting. (30-33) 
Therefore, there is a need to optimize 
the design, formulation and potential 
applications of anionic nanocomplexes. 
Thus, the additional assembly of LPR 
and HA at the optimized ratio was 
investigated for in vivo circulation and 
specific delivery to tumor through 
enhanced permeability and retention 
(EPR) effect and active target of CD44 
and EGFR overexpressed on the surface 
of cancer cells. The highly negative 
charge and much better stability of 
HLPR compared to LPR in the serum, 
indicated that HA could tightly coat on 
the surface of the disordered lipid layer 
of DOTAP/DOPE mainly through 
electrostatic interaction. Moreover, 
some of the other noncovalent bonding, 
such as hydrogen bond between HA and 
the exposure acid amine sequences of 
the multifunctional peptide component 
(23), further stabilized the adherence of 
HA component on the surface of LPR. 
Given that GE11 assisted in cellular 
internalization mainly via the 
clathrin-mediated endocytosis pathway 
(34), we studied the cell uptake 
mechanism of HLPR in the presence of 
anti-CD44-antibody and chlorpromazine 
(an inhibitor of clathrin-dependent 
endocytosis) (35) to investigate the 
targeting function of HA and GE11. The 
results indicated that both HA and 
siRNA components of HLPR entered 
HCCLM3 cells through 
CD44-independent and 
clathrin-dependent pathways. The 
findings here show that HA and siRNA 
components of HLPR did not dissociate 
from each other before being 
endocytosed. This study indirectly 
proved that the structure of HLPR was 
similar with that of LPR and GE11 
sequences of multifunctional peptide 
component partially protruding outside 
of HLPR (Figure 1A). 
 
 In vitro, HLPR had comparable 
siRNA delivery efficiency with LPR and 
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L2K This finding showed that HA not 
only shielded the positive charge of LPR 
but also improved the affinity of 
negatively charged nanocomplexes to 
tumor cells through the dual-targeting 
by HA and GE11 sequences of CD44 
and EGFR, respectively, that are 
overexpressed on the surface of 
HCCLM3 cells. This factor is a special 
advantage of HA to actively bind to the 
cancer cells compared with the other 
anionic polymers. Interestingly, we 
found that HA began to dissociate from 
the nanocomplexes after HLPR was 
endocytosed by HCCLM3 cells (Figures 
3C and D). The in vivo siRNA delivery 
results also indicated that HLPR were 
stable enough to circulate in the blood. 
There was fluorescence detected in other 
organs (mainly in the kidneys and some 
in the lung and liver) but this could be 
attributed to the time point of imaging. 
Later time points (e.g. 24 hours) would 
potentially show more accumulation in 
the tumor and far less in first-pass 
organs such as the kidneys.(36) Overall 
the tissue distributions of Cy5-siRNA 
fluorescence in vivo, show that HLPR 
formulation firstly utilized the 
electronegativity of HA resulting in 
extended circulation lifetimes and then 
demonstrated the ability to specifically 
target CD44 for enhanced adhesion to 
the tumor.  As shown in Figure 1A on 
the model of HLPR construction, the 
HA component looked similar to an 
“outerwear with many little bores” on 
the surface of LPR nanocomplexes, and 
the GE11 sequences partially protrude 
from the bores. Then, the anchored 
GE11 sequences on the surface of HLPR 
strongly bound the EGFR that is 
overexpressed on the cancer cell surface, 
and HLPR was endocytosed through an 
EGFR-mediated pathway, which is a 
smart process of HLPR to overcome the 
extracellular biological barriers. During 
endocytosis, the HA component of 
HLPR probably started to dissociate 
from LPR. Next, DOPE disrupted the 
endosomal membrane(37) to release 
siRNA and peptide/siRNA complexes 
into the cytoplasm. The proposed 
pathway of the HLPR smart vector is 
shown in Figure S3. We found that 
HLPR was a suitable tumor-targeting 
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delivery system for anticancer treatment 
in the tumors that overexpress at the cell 
surface CD44 and EGFR proteins. The 
liver and kidney biochemical assays and 
the weight of mice that was unaffected 
by the repeat administration regime, 
demonstrated that the HLPR vectors 
were nontoxic in vivo. The great 
inhibition of tumor growth in the 
HLPR-survivin group compared with 
that of the other groups and, in addition, 
the extensive apoptosis and necrosis of 
tumors, indicated that HLPR was a 
highly efficient siRNA delivery system 
and has the potential for clinically 
pharmaceutical applications. As tumor 
progression is complex to study and 
target with a single target gene, in the 
future we will investigate whether 
combination therapy (e.g. multiple 
siRNAs) can not only inhibit tumor 
growth but also reduce tumor volume. 
 
 From the above investigation, we 
found that HLPR is a novel attractive 
self-assembled system compared with 
the universal lipopolyplexes (38) and 
PEGylated RTNs reported previously 
(39). Lipopolyplexes always consist of a 
polyplex core and a liposomal shell, 
which had to conjugate in turn with PEG 
and targeting ligands to achieve targeted 
delivery. For PEGylated RTNs, the PEG 
chains and integrin-targeting peptides 
protrude from the same disordered lipid 
layer. The PEG chains would weaken 
the targeting function of 
integrin-targeting peptides, and the 
optimized percentage of PEG and 
targeting moieties are always difficult to 
control accurately. Thus, the 
pharmaceutical preparation of 
PEGylated RTNs is challenging to 
produce, indicating that PEGylation of 
RTNs would either reduce the delivery 
capability of siRNA vectors or 
incompletely shield the positive charge. 
HLPR formulation overcomes the 
disadvantages of universal 
lipopolyplexes and RTNs. A postulated 
mechanism for the efficient transfection 
of HLPR nanocomplexes is described. 
This study supports a novel and rational 
strategy for effective siRNA delivery in 
vivo. 
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Figure legends 
 
Figure 1 Formulation and physiochemical characterization of LPR and HLPR. (A) 
Schematic diagram of the model construction of LPR and HLPR. (B) Distribution of 
diameter (b1), zeta potential (b2), and the morphology observed from TEM of LPR 
(b3). (C) Distribution of diameter (c1), zeta potential (c2), and the morphology 
observed from TEM of HLPR (c3). (D) Particle size and zeta potential with time of 
LPR and HLPR in 5% (w/v) bovine serum albumin. (E) Stability assay of LPR and 
HLPR in the serum at 0, 2, 4, 6, 7.5, 9, and 12 h. 1 represents fetal bovine serum, 2 
represents naked siRNA, 3 represents LPR, 4 represents HLPR, and 5 represents the 
marker. 
 
Figure 2 (A) Cellular uptake of Cy5-siRNA of LPR and HLPR and (B) cell uptake of 
FITC-HA of HLPR in HCCLM3 cells incubated for 4 h in the absence of any 
inhibitor (Normal) and in the presence of anti-CD44-antibody or chlorpromazine (an 
inhibitor of clathrin-dependent endocytosis). (C) and (D) Confocal microscopic 
images of the intracellular localization of HLPR identified by FITC-HA (green) and 
Cy5-siRNA (red) after being incubated with HCCLM3 cells for 45 min and 4 h, 
respectively. The nucleus is identified using DAPI (blue). Panels C1–D1 indicate 
DAPI-labeled nucleus (blue). Panels C2–D2 show FITC-HA (green). Panels C3–D3 
identify the localization of Cy5-siRNA (red). C4–D4 represent the merged images 
showing the localization of FITC-HA (green) and Cy5-siRNA (red) and nucleus 
(blue). Scale bar = 12.5 μm for all images. 
 
Figure 3 (A) Cytotoxicity of nanocomplexes in HCCLM3 cells 4 h after transfection. 
(B) Relative expression of survivin gene at the mRNA level in HCCLM3 cells 
compared with that of negative control siRNA packaged by Lipofectamine 2000, LPR, 
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and HLPR incubated for 48 h. (C) Apoptosis assay in HCCLM3 cells staining nucleus 
with hochest33342.  
 
Figure 4 (A) Tissue distribution of Cy5-siRNA in the heart, liver, spleen, lung, 
kidneys, and tumor 6 h after an intravenous injection of physiological saline 
(Untreated), naked Cy5-siRNA (siRNA), and HLPR complexes containing 
Cy5-siRNA (HLPR), respectively. Color scale: min = 1.5 × 10
8
, max = 4 × 10
9
. (B) 
Mean fluorescence intensity of Cy5-siRNA in the different groups at the 6 h time 
point.  
 
Figure 5 In vivo liver and kidney functional markers and the concentration of blood 
glucose examined in the peripheral blood of mice.  
 
Figure 6 In vivo antitumor efficacy of siRNA administrations. (A) The tumor growth, 
(B) the weight changes of mice, (C) the tumor weights, and (D) the tumor images of 
each group of mice (n=5) after eight administrations (every other day).  
 
Figure 7 Histological assessments of tumors following eight administrations every 
other day. (A) Hematoxylin–eosin (H&E), (B) TdT-mediated dUTP nick-end labeling 
(TUNEL), and (C) immunohistochemistry staining assay. A1–C1 represent the 
untreated group. A2–C2 represent the naked siRNA group. A3–C3 represent the 
HLPR-negative control siRNA (HLPR-negative) group. A4–C4 represent the 
HLPR-survivin group. 
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